Forgot Your Password? Enter your email address below to reset your password. We will email you a link to create a new password.
Dr. Cynthia Bamdad Presents at ISCT Montreal. Room 519AB, Thursday, May 3, 2018 at 11:00 AM.
Dr. Cynthia Bamdad, CEO of Minerva Biotechnologies, will present a talk entitled, “Novel CAR T that Targets MUC1* Not Full-Length MUC1 for Treatment of Solid Tumor Cancers” at the annual meeting of the International Society for Cellular Therapy (ISCT) in Montreal, May 3-5, 2018. The talk presents the pre-clinical development, and safety and efficacy data for a CAR T that targets a novel antigen that is present on over 75% of solid tumor cancers. IND-enabling safety data from human tissue studies and in vivo data will be presented.
Minerva developed a CAR T therapeutic that guides patient immune cells to the tumor via an antibody that binds to a novel tumor-associated antigen called MUC1* (muk 1 star). The transmembrane cleavage product, MUC1*, is the powerful growth factor receptor that drives tumor growth. This will be a first-in-human trial since every other MUC1-targeting therapeutic, tested in humans, targeted full-length MUC1. Studies show that MUC1 cleavage increases as tumor stage increases; previous attempts targeted epitopes on the portion of MUC1 that is shed from the cell surface after cleavage.
The human antibody fragment, which guides the anti-MUC1* CAR T to the tumor, binds to an epitope that is masked on full-length MUC1, so the CAR T does not bind to normal, healthy cells. In addition, this antibody competitively inhibits the binding of metastatic growth factor NME7AB to the MUC1* growth factor receptor.
If you are attending ISCT, the talk will be in room 519AB on Thursday, May 3, 2018 at 11:00 AM.